The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ITOC 2022 | Armoring anti-HER2 CAR-T cells with CCR8 and a DNR to enable efficacy in solid tumor models
Thaddäus Strzalkowski, Ludwig-Maximilians-Universität München, Munich, Germany, talks on armoring anti-HER2 CAR-T cells with C-C-motive receptor 8 (CCR8) and a dominant negative TGF-b receptor (DNR) to enable CAR-T cell efficacy in solid tumor models. Through investigation via primary murine and human T-cells, as well as murine models, it was demonstrated that the expression of CCR8 can redirect CAR T cells to the tumor and a DNR can prevent immunosuppression of CAR T cells in the tumor microenvironment. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
